Cart
sales@molnova.com
Auristatin23
CAS No. 2375388-36-4
Auristatin23( —— )
Catalog No. M35946 CAS No. 2375388-36-4
Auristatin23 is an Antitumor agent. Auristatin23 exhibits antiproliferative activity on tumor cell lines.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 174 | In Stock |
|
| 5MG | 107 | In Stock |
|
| 10MG | 157 | In Stock |
|
| 25MG | 236 | In Stock |
|
| 50MG | 324 | In Stock |
|
| 100MG | 442 | In Stock |
|
| 200MG | 594 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAuristatin23
-
NoteResearch use only, not for human use.
-
Brief DescriptionAuristatin23 is an Antitumor agent. Auristatin23 exhibits antiproliferative activity on tumor cell lines.
-
DescriptionAuristatin23 is an Antitumor agent. Auristatin23 exhibits antiproliferative activity on tumor cell lines.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2375388-36-4
-
Formula Weight917.23
-
Molecular FormulaC49H84N6O10
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES[C@H]([C@H](C(N[C@@H](CC1=CC=CC=C1)C(O)=O)=O)C)(OC)[C@]2(N(C(C[C@H]([C@@H](N(C([C@@H](NC([C@@H](N(CCCCN(C(OC(C)(C)C)=O)C)C)[C@@H](C)C)=O)C(C)C)=O)C)[C@H](CC)C)OC)=O)CCC2)[H]
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Cyanidin-3-O-arabino...
Cyanidin-3-O-arabinoside chloride has antioxidant activity. It reduces the peroxynitrite-induced suppression of mitochondrial respiration, DNA damage, PARS activation and vascular dysfunction in HUVECs.
-
3-Phosphoglyceric ac...
3-Phosphoglyceric acid is a metabolic intermediate in glycolysis and the Calvin cycle, and it is also involved in alveolar macrophage epigenetic regulation.
-
RMC-6291
RMC-6291 is an orally active, covalent inhibitor of KRAS G12C (ON) that forms a tri-complex within tumor cells between KRAS G12C (ON) and cyclophilin A (CypA), thereby preventing KRAS G12C (ON) from signaling via steric blockade of RAS effector binding and eliciting deep and durable suppression of RAS pathway activity in KRAS G12C tumor models .
